This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer’s disease dementia

Authors

Claxton, Amy, Baker, Laura D., Hanson, Angela, Trittschuh, Emily H., Cholerton, Brenna, Morgan, Amy, Callaghan, Maureen, Arbuckle, Matthew, Behl, Colin, Craft, Suzanne

Journal

Journal of Alzheimer's Disease, Volume: 44, No.: 3, Pages.: 897-906

Year of Publication

2015

Abstract

[Correction Notice: An Erratum for this article was reported in Vol 45(4) of Journal of Alzheimer’s Disease (see record [rid]2015-17286-023[/rid]). In the original article, Tables 1 and 2 were missing. Tables 1 and 2 are present in the erratum.] Previous trials have shown promising effects of intranasally administered insulin for adults with Alzheimer’s disease dementia (AD) or amnestic mild cognitive impairment (MCI). These trials used regular insulin, which has a shorter half-life compared to long-lasting insulin analogues such as insulin detemir. The current trial examined whether intranasal insulin detemir improves cognition or daily functioning for adults with MCI or AD. Sixty adults diagnosed with MCI or mild to moderate AD received placebo (n = 20), 20 IU of insulin detemir (n = 21), or 40 IU of insulin detemir (n = 19) for 21 days, administered with a nasal drug delivery device. Results revealed a treatment effect for the memory composite for the 40 IU group compared with placebo (p < 0.05). This effect was moderated by APOE status (p < 0.05), reflecting improvement for APOE-ε4 carriers (p < 0.02), and worsening for non-carriers (p < 0.02). Higher insulin resistance at baseline predicted greater improvement with the 40 IU dose (r = 0.54, p < 0.02). Significant treatment effects were also apparent for verbal working memory (p < 0.03) and visuospatial working memory (p < 0.04), reflecting improvement for subjects who received the high dose of intranasal insulin detemir. No significant differences were found for daily functioning or executive functioning. In conclusion, daily treatment with 40 IU insulin detemir modulated cognition for adults with AD or MCI, with APOE-related differences in treatment response for the primary memory composite. Future research is needed to examine the mechanistic basis of APOE-related treatment differences, and to further assess the efficacy and safety of intranasal insulin detemir. (PsycINFO Database Record (c) 2015 APA, all rights reserved). (journal abstract)

Keywords

alzheimer’s disease, clinical trials, cognitive impairment, insulin, intranasal drug administration, mild cognitive impairment, randomized

Countries of Study

USA

Types of Dementia

Alzheimer’s Disease, Mild Cognitive Impairment (MCI)

Types of Study

Randomised Controlled Trial

Type of Outcomes

ADLs/IADLs, Cognition

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Other